Table 6
From the following article
India's health biotech sector at a crossroads
Sarah E Frew, Rahim Rezaie, Stephen M Sammut, Monali Ray, Abdallah S Daar & Peter A Singer
Nature Biotechnology 25, 403 - 417 (2007)
doi:10.1038/nbt0407-403
Table 6. IP portfolios/marketing rights for companies intervieweda
| Company name | Information on significant patents |
|---|---|
aPatents may include and are not limited to: biological and pharmaceutical products, development processes, drug delivery platforms, and others. | |
| Avestha Gengraine Technologies | Currently has  60 patent applications, 22 of which are filed under Patent Cooperation Treaty (PCT), including two rice patents filed in the US. Range of technologies include: molecular markers, transgenic plants, novel proteins and methodologies. A patent for 'pearl Millet' has already been granted in South Africa and Australia |
| Bharat Biotech International | Approximately 20 patents overall. (A novel process for preparation and purification of hepatitis-B surface protein (HIMAX) in India; Expression of recombinant streptokinase in US, Expression of recombinant mature lysostaphin-BH005; works against MRSA, Vero adaptation of rotavirus vaccines, S. aureus vaccine) |
| Bharat Serum and Vaccines | Patents granted for novel formulations in US (amphotericin emulsion, lipid free propofol), in Europe (Ifosfamide with Mesna, amphoptericin B lipid complex). Other patents on these and other drug delivery systems at various stages in 40–70 countries |
| Bhat Bio-Tech India | Currently applying for a few patents, both in India and abroad, for tri-line HIV test and combo-test for HIV and HCV |
| Biocon | Patent portfolio of over 300 patents including 15 US patents including some for fermentation devices and various processes for production of certain therapeutics and over 100 innovation patent applications are at various phases. Its recent acquisition of Nobex gave Biocon IP rights to IN-105 (an oral insulin), BN-054 (an oral peptide for cardiovascular disease), Oratonin (an oral calcitonin in phase 1 trials for osteoporosis), Oral PTH (parathyroid hormone) and APAZA (in phase 1/2 trials for inflammatory bowel disease) |
| GangaGen Biotechnologies | Has two US patents: One for a genetically modified lysogenic phage (to be used as an anti-bacterial agent) and another on utilizing phages to develop whole cell vaccines |
| Indian Immunologicals | Applied for novel combination of rabies combination vaccine (made up of conventional rabies vaccine and a DNA plasmid) in a number of countries and has already been granted in South Africa |
| Nicholas Piramal India | A portfolio of 36 patents and 173 patent applications at various stages |
| Panacea Biotec | Seven products patented in the US and 4 in Canada and numerous patent applications in the pipeline including 18 PCT applications. The exclusive products based on patented drug delivery system include: Xeed (for optimum bioavailability of rifampicin), nimulid safeinject (parenteral formulation of nimesulide), panimun bioral (cyclosporine modified formulation), ThankGod (Euphorbia prostrata extract for management of hemorrhoids), Nimulid MD (nimesulide tablets), Willgo (nimesulide formulation), Nimulid Transgel (nimesulide transdermal gel), Nimcet (combination of nimesulide + cetrizine) and ODPEP (pantaprosole+domeperidone). The company has filed 316 applications worldwide and 129 in India |
| Reliance Life Sciences | Currently has 130 patent applications in different stages of approval |
| Shantha Biotechnics | Product patent portfolio with Shantha West, for monoclonal antibodies. One US patent granted and four more at various stages. Seven patents under review in India and three have been granted. Patent activities span hepatitis B process patents, insulin process patent, antibodies that recognize hyperproliferative cells and methods of making and using these cells |
| Strand Life Sciences | Mainly protects products by keeping source code private, but has also filed a few provisional patents |
| Transgene Biotek | US patent on oral delivery platform for insulin, and in the process of filing many more patents |
| Wockhardt | 150 patent applications submitted so far including three in pharmaceutical biotech covering their protein expression systems |